Liège, Belgium and Manchester, UK; August 2025: AARDEX Group, a global leader in digital medication adherence solutions, and Pill Connect, a pioneer in connected dispensing technology, have announced a strategic partnership to support a multi-cohort Phase 2A dose selection trial. Together, the two companies are enabling a new standard in clinical research by combining digital innovation with real-time adherence tracking and intelligent dose management.
The clinical trial will implement a fully integrated electronic monitoring system where patients’ medication intake will be tracked in real time from their homes using Pill Connect’s connected dispenser paired and AARDEX’ MEMS® Mobile app that will centralize adherence data to the with MEMS AS®, the dedicated Medication Adherence Software Platform developed by AARDEX Group. The system will enable clinical teams to remotely monitor dose timing, total daily dose taken, and adherence to prescribed protocols, offering a holistic view of each patient’s dosing behavior throughout the study.
Meanwhile, patients will benefit from a user-friendly interface, the ability to set personalized medication reminders, and receive real-time notifications to stay on track, all aimed at promoting engagement and empowering participants in their treatment journey.
“Adherence is one of the key drivers of variability in drug exposure,” said Bernard Vrijens, CEO of AARDEX Group. “Through this collaboration, we’re enabling sponsors to accurately measure and optimize dosing behavior in a real-world setting. The combination of real-time adherence insights and intelligent drug dispensing marks a significant leap forward in trial quality and data integrity.”
James Burnstone, CEO of Pill Connect, commented: “Our mission has always been to improve adherence monitoring, through accurate, per-pill data in a form that’s intuitive and acceptable to patients. By combining this with AARDEX’s trusted and proven adherence analytics, we’re creating a powerful, end-to-end solution. Ultimately, it’s about improving patient engagement with adherence tools as only with engaged participants can we generate the high-quality data needed to drive confident clinical decisions and maximise trial impact.”
This joint solution addresses one of the most persistent challenges in clinical research: ensuring that patients take medications as intended, consistently and accurately, especially in outpatient settings. By combining objective, high-resolution adherence data with digital dose management, the partnership supports faster and more reliable identification of optimal therapeutic doses.
Ultimately, this collaboration reflects a shared vision of a more personalized, precise, and efficient drug development process, one that leverages the full potential of connected health technologies to improve outcomes for patients and trial sponsors alike.
About AARDEX Group. AARDEX Group is a global leader in medication adherence monitoring for clinical trials. With more than 30 years of experience, AARDEX provides state-of-the-art digital tools that enable pharmaceutical sponsors and research teams to collect, analyze, and act on real-time adherence data, improving data quality, patient safety, and trial success.
About Pill Connect. Pill Connect is a UK-based MedTech company revolutionizing the way medication is taken and tracked. Its patented smart capsule dispenser that allows personalized dosing, real-time monitoring, and seamless data transfer. Pill Connect empowers both patients and clinicians with actionable insights that improve adherence and treatment outcomes.
For more information, please contact:
Bernard Vrijens
CEO, Aardex Group
bernard.vrijens@aardexgroup.site
James Burnstone
CEO, Pill Connect
james@pill-connect.com
